Clinical Trial Update: Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease [Phase 2]

View source ↗

Summary

Phase 2 trial results evaluate methylene blue for healthy aging, mild cognitive impairment, and Alzheimer's disease, with results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment

Drugs mentioned

• METHYLENE BLUE (METHYLENE BLUE)

Snippet

Sponsor: The University of Texas Health Science Center at San Antonio | Conditions: Mild Cognitive Impairment, MCI | Phase 2 | Status: COMPLETED | Results posted: 2024-09-19